Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx


A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)




This is for a randomized clinical trial (RCT) to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in patients with relapsing-remitting (RR) multiple sclerosis (MS).

Study Status: Active, not recruiting


Condition Intervention Phase
Relapsing Remitting Multiple Sclerosis Drug: Interferon beta 1-a
Drug: glatiramer acetate
Other: placebo
Phase 3

Verified by Fred Lublin April, 2012

Sponsored by: Fred Lublin
Information provided by: Mount Sinai School of Medicine identifier: NCT00211887

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio
United States

Fred Lublin, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site